Global Peripheral Arterial Disease (PAD) Therapeutics Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 92

Report ID: 1230

Peripheral artery disease (PAD) is a narrowing of the arteries other than those that supply the heart or the brain. When narrowing occurs in the heart, it is called coronary artery disease, while, in the brain, it is called cerebrovascular disease. Peripheral artery disease most commonly affects the legs, but other arteries may also be involved. The classic symptom is leg pain when walking which resolves with rest, known as intermittent claudication. Other symptoms including skin ulcers, bluish skin, cold skin, or poor nail and hair growth may occur in the affected leg. Complications may include an infection or tissue death which may require amputation; coronary artery disease, or stroke.[3] Up to 50% of cases of PAD are without symptoms.
In 2018, the global Peripheral Arterial Disease (PAD) Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Peripheral Arterial Disease (PAD) Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Peripheral Arterial Disease (PAD) Therapeutics development in United States, Europe and China.

The key players covered in this study
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)

Market segment by Type, the product can be split into
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others

Market segment by Application, split into
Hospitals
Clinics
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Peripheral Arterial Disease (PAD) Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Peripheral Arterial Disease (PAD) Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Peripheral Arterial Disease (PAD) Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size Growth Rate by Type (2014-2025)
1.4.2 Anti-Platelet Drugs
1.4.3 Dual Antiplatelet Therapy Drugs
1.4.4 Others
1.5 Market by Application
1.5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Peripheral Arterial Disease (PAD) Therapeutics Market Size
2.2 Peripheral Arterial Disease (PAD) Therapeutics Growth Trends by Regions
2.2.1 Peripheral Arterial Disease (PAD) Therapeutics Market Size by Regions (2014-2025)
2.2.2 Peripheral Arterial Disease (PAD) Therapeutics Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Peripheral Arterial Disease (PAD) Therapeutics Market Size by Manufacturers
3.1.1 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Manufacturers (2014-2019)
3.1.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Peripheral Arterial Disease (PAD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players Head office and Area Served
3.3 Key Players Peripheral Arterial Disease (PAD) Therapeutics Product/Solution/Service
3.4 Date of Enter into Peripheral Arterial Disease (PAD) Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type (2014-2019)
4.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application (2014-2019)

5 United States
5.1 United States Peripheral Arterial Disease (PAD) Therapeutics Market Size (2014-2019)
5.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in United States
5.3 United States Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
5.4 United States Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application

6 Europe
6.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size (2014-2019)
6.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Europe
6.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
6.4 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application

7 China
7.1 China Peripheral Arterial Disease (PAD) Therapeutics Market Size (2014-2019)
7.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in China
7.3 China Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
7.4 China Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application

8 Japan
8.1 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size (2014-2019)
8.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Japan
8.3 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
8.4 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size (2014-2019)
9.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Southeast Asia
9.3 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
9.4 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application

10 India
10.1 India Peripheral Arterial Disease (PAD) Therapeutics Market Size (2014-2019)
10.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in India
10.3 India Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
10.4 India Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application

11 Central & South America
11.1 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size (2014-2019)
11.2 Peripheral Arterial Disease (PAD) Therapeutics Key Players in Central & South America
11.3 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type
11.4 Central & South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application

12 International Players Profiles
12.1 AstraZeneca Plc. (UK)
12.1.1 AstraZeneca Plc. (UK) Company Details
12.1.2 Company Description and Business Overview
12.1.3 Peripheral Arterial Disease (PAD) Therapeutics Introduction
12.1.4 AstraZeneca Plc. (UK) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2014-2019)
12.1.5 AstraZeneca Plc. (UK) Recent Development
12.2 Bayer HealthCare Pharmaceuticals (Germany)
12.2.1 Bayer HealthCare Pharmaceuticals (Germany) Company Details
12.2.2 Company Description and Business Overview
12.2.3 Peripheral Arterial Disease (PAD) Therapeutics Introduction
12.2.4 Bayer HealthCare Pharmaceuticals (Germany) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2014-2019)
12.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Development
12.3 Bristol-Myers Squibb Company (US)
12.3.1 Bristol-Myers Squibb Company (US) Company Details
12.3.2 Company Description and Business Overview
12.3.3 Peripheral Arterial Disease (PAD) Therapeutics Introduction
12.3.4 Bristol-Myers Squibb Company (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2014-2019)
12.3.5 Bristol-Myers Squibb Company (US) Recent Development
12.4 Merck & Co., Inc. (US)
12.4.1 Merck & Co., Inc. (US) Company Details
12.4.2 Company Description and Business Overview
12.4.3 Peripheral Arterial Disease (PAD) Therapeutics Introduction
12.4.4 Merck & Co., Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2014-2019)
12.4.5 Merck & Co., Inc. (US) Recent Development
12.5 Proteon Therapeutics, Inc. (US)
12.5.1 Proteon Therapeutics, Inc. (US) Company Details
12.5.2 Company Description and Business Overview
12.5.3 Peripheral Arterial Disease (PAD) Therapeutics Introduction
12.5.4 Proteon Therapeutics, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2014-2019)
12.5.5 Proteon Therapeutics, Inc. (US) Recent Development
12.6 Sanofi S.A. (France)
12.6.1 Sanofi S.A. (France) Company Details
12.6.2 Company Description and Business Overview
12.6.3 Peripheral Arterial Disease (PAD) Therapeutics Introduction
12.6.4 Sanofi S.A. (France) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2014-2019)
12.6.5 Sanofi S.A. (France) Recent Development
12.7 Symic Bio, Inc. (US)
12.7.1 Symic Bio, Inc. (US) Company Details
12.7.2 Company Description and Business Overview
12.7.3 Peripheral Arterial Disease (PAD) Therapeutics Introduction
12.7.4 Symic Bio, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2014-2019)
12.7.5 Symic Bio, Inc. (US) Recent Development
12.8 TheraVasc Inc. (US)
12.8.1 TheraVasc Inc. (US) Company Details
12.8.2 Company Description and Business Overview
12.8.3 Peripheral Arterial Disease (PAD) Therapeutics Introduction
12.8.4 TheraVasc Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2014-2019)
12.8.5 TheraVasc Inc. (US) Recent Development
12.9 AnGes MG, Inc. (Japan)
12.9.1 AnGes MG, Inc. (Japan) Company Details
12.9.2 Company Description and Business Overview
12.9.3 Peripheral Arterial Disease (PAD) Therapeutics Introduction
12.9.4 AnGes MG, Inc. (Japan) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2014-2019)
12.9.5 AnGes MG, Inc. (Japan) Recent Development
12.10 Athersys, Inc. (US)
12.10.1 Athersys, Inc. (US) Company Details
12.10.2 Company Description and Business Overview
12.10.3 Peripheral Arterial Disease (PAD) Therapeutics Introduction
12.10.4 Athersys, Inc. (US) Revenue in Peripheral Arterial Disease (PAD) Therapeutics Business (2014-2019)
12.10.5 Athersys, Inc. (US) Recent Development
12.11 Betagenon AB (Sweden)
12.12 miRagen Therapeutics, Inc. (US)
12.13 Multi Gene Vascular Systems Ltd (Israel)
12.14 ViroMed Co. Ltd. (Korea)

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details